The effect of rosiglitazone on expressions of IL-18, MCP-1 and MMP-9 in rabbits with atherosclerosis / 中国药学杂志
Chinese Pharmaceutical Journal
;
(24): 1621-1625, 2012.
Artigo
em Chinês
| WPRIM
| ID: wpr-860589
ABSTRACT
OBJECTIVE:
To compare the effects of rosiglitazone and simvastatin on inflammatory factors in atherosclerotic rabbits and to explore the anti-atherosclerosis mechanism.METHODS:
Thirty-six male New Zealand rabbits were randomly divided into four groups control group, model group, simvastatin group, and rosiglitazone group. Subcutaneous injection of dl-homocyesteine thiolac-tone combined with high fat diet was used to reproduce atherosclerotic rabbit model, the serum level of interleukin-18 (IL-18) was examined by ELISA, and the expressions of monocyte chemoattractant-1 (MCP-1) and matrix metalloproteinase-9 (MMP-9) in aortic atherosclerotic plaque were examined by immunohistochemistry.RESULTS:
Compared with the control group, the serum levels of IL-18 and the expressions of MMP-9 and MCP-1 in aortic atherosclerotic plaque were increased obviously in the other three groups (P0.05).CONCLUSION:
Rosiglitazone can decrease the serum level of IL-18 and the expressions of MCP-1 and MMP-9 in aortic atherosclerotic plaque, and inhibit the development of atherosclerosis. The mechanism is related to anti-inflammation.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Chinese Pharmaceutical Journal
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS